Summary
Glucagon Like Peptide 2 Receptor (GLP2R) - Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition.
Glucagon Like Peptide 2 Receptor (GLP2R) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 7, 1 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Immunology, Metabolic Disorders, Musculoskeletal Disorders and Other Diseases which include indications Short Bowel Syndrome, Graft Versus Host Disease (GVHD), Crohn's Disease (Regional Enteritis), Inflammation, Multiple Organ Failure (Multiple Organ Dysfunction Syndrome), Osteoporosis, Unspecified Gastrointestinal Disorders and Unspecified Metabolic Disorders.
The latest report Glucagon Like Peptide 2 Receptor - Drugs In Development, 2021, outlays comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R)
- The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glucagon Like Peptide 2 Receptor (GLP2R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glucagon Like Peptide 2 Receptor (GLP2R) - Overview
Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glucagon Like Peptide 2 Receptor (GLP2R) - Companies Involved in Therapeutics Development
9 Meters Biopharma Inc
Applied Molecular Transport Inc
Bainan Biotech ApS
Entera Bio Ltd
Hanmi Pharmaceuticals Co Ltd
Huons Global Co Ltd
OPKO Health Inc
PhaseBio Pharmaceuticals Inc
Sosei Group Corp
Tasly Pharmaceutical Group Co Ltd
VectivBio Holding AG
Zealand Pharma AS
Glucagon Like Peptide 2 Receptor (GLP2R) - Drug Profiles
apraglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dapiglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Agonize GIP and GLP-2 for Osteoporosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Agonize GLP2R for Short Bowel Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Agonize GLP2R for Short Bowel Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glepaglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXG-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HL-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-15912 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOD-1501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Agonize GLP2R for Intestinal Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Agonize GLP2R for Unspecified Gastrointestinal Diseases and Unspecified Metabolic Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teduglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teduglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teduglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glucagon Like Peptide 2 Receptor (GLP2R) - Dormant Products
Glucagon Like Peptide 2 Receptor (GLP2R) - Discontinued Products
Glucagon Like Peptide 2 Receptor (GLP2R) - Product Development Milestones
Featured News & Press Releases
Aug 19, 2021: Zealand Pharma announces first patient dosed in EASE-SBS 4 phase 3b trial assessing glepaglutide in patients with short bowel syndrome
Jun 29, 2021: Zealand Pharma to present data on glepaglutide at the 17th Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA)
Jun 24, 2021: VectivBio receives FDA Orphan Drug Designation for apraglutide for acute graft-versus-host disease
Jun 23, 2021: Takeda Pharmaceutical : Obtaining manufacturing and marketing approval for "Revestive", the first treatment for short bowel syndrome in Japan
Jun 15, 2021: VectivBio announces first patient dosed in metabolic balance study of apraglutide in colon-in-continuity patients with short bowel syndrome with intestinal failure
Apr 07, 2021: Hanmi's short bowel syndrome drug gets FDA fast-track status
Feb 03, 2021: VectivBio announces first patient dosed in pivotal phase 3 trial of Apraglutide for the treatment of short bowel syndrome
Feb 03, 2021: VectivBio announces first patient dosed in pivotal phase 3 trial of Apraglutide for the treatment of short bowel syndrome
Dec 09, 2020: 9 Meters Biopharma receives orphan drug designation for NM-003, a proprietary long-acting GLP-2, for prevention of acute graft versus host disease (aGvHD)
Jul 01, 2020: Hanmi Pharm’s short-bowel syndrome drug wins FDA’s rare pediatric disease status
Feb 10, 2020: The Scottish Medicines Consortium advises on newly licensed medicine Revestive for use by NHSScotland
Jun 26, 2019: Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome
May 17, 2019: Therachon to present data from ongoing Phase II Study of Apraglutide for Short Bowel Syndrome at Digestive Disease Week
May 17, 2019: U.S. FDA approves GATTEX (teduglutide) for children 1 year of age and older with Short Bowel Syndrome
May 07, 2019: Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by 9 Meters Biopharma Inc, 2021
Pipeline by Applied Molecular Transport Inc, 2021
Pipeline by Bainan Biotech ApS, 2021
Pipeline by Entera Bio Ltd, 2021
Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021
Pipeline by Huons Global Co Ltd, 2021
Pipeline by OPKO Health Inc, 2021
Pipeline by PhaseBio Pharmaceuticals Inc, 2021
Pipeline by Sosei Group Corp, 2021
Pipeline by Tasly Pharmaceutical Group Co Ltd, 2021
Pipeline by VectivBio Holding AG, 2021
Pipeline by Zealand Pharma AS, 2021
Dormant Projects, 2021
Discontinued Products, 2021
List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
